April 1, 2024Journal of Cardiac FailureOpen Access

High Circulating Dipeptidyl Peptidase 3 Predicts Mortality and Need for Organ Support in Cardiogenic Shock: An Ancillary Analysis of the ACCOST-HH Trial

View Full Paper

Ask AI

Bookmark

Authors

APAdrien PicodHeart Failure / Cardiomyopathy HNHugo NordinInserm DJDominik JarczakUniversität Hamburg

Discussion

Member takes

Implication

Ancillary trial analysis reveals circulating dipeptidyl peptidase 3 predicts mortality and organ support in cardiogenic shock, highlighting its value for risk stratification.

Key Points

Elevated circulating dipeptidyl peptidase 3 predicts short-term mortality and an increased need for organ support across diverse cohorts presenting with cardiogenic shock.
An ancillary analysis of the ACCOST-HH trial evaluated circulating dipeptidyl peptidase 3 across heterogeneous shock etiologies beyond strictly ischemic presentations.
Measuring circulating dipeptidyl peptidase 3 supports improved risk stratification and highlights potential targetable molecular pathways in refractory cardiogenic shock.

Cite This Study

Picod et al. (2024) studied this question.

synapsesocial.com/papers/68e70ef4b6db643587688561 https://doi.org/10.1016/j.cardfail.2024.03.014

View Full Paper

Ask AI

Bookmark

Implication

Ancillary trial analysis reveals circulating dipeptidyl peptidase 3 predicts mortality and organ support in cardiogenic shock, highlighting its value for risk stratification.

High Circulating Dipeptidyl Peptidase 3 Predicts Mortality and Need for Organ Support in Cardiogenic Shock: An Ancillary Analysis of the ACCOST-HH Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

High Circulating Dipeptidyl Peptidase 3 Predicts Mortality and Need for Organ Support in Cardiogenic Shock: An Ancillary Analysis of the ACCOST-HH Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider